 1. Patients with high risk multiple myeloma who are transplant candidates, in partial response PR or better. High risk will be defined as patients with any of the following: a. Fluorescence in situ hybridization showing t4:14, t14:16t 14:20 deletion Del 1717p or gain amp 1q; b. Deletion 13 by conventional cytogenetic analysis; c. High risk signatures as determined by the GEP-70 or EMC-92 gene expression profiles; d. Relapsed disease within 18 months of prior ASCT. 